Biophytis shares and BSA trading is suspended pending a new
Paris (France), Cambridge (Massachusetts, USA), May 7, 2020, 7:30 p.m. CEST -
BIOPHYTIS (Euronext Growth Paris) asked Euronext Paris to suspend the trading
of its shares (ISIN code : FR0012816825-ALBPS) and BSA (ISIN code :
FR0013507290-BPSBS) as from today the 7th of May 2020, pending the publication
of a new press release.
Biophytis SA is a clinical-stage biotechnology company specialized in the
development of drug candidates to slow down degenerative processes and improve
functional abilities in patients with age-related diseases, especially
Sarconeos (BIO101), our leading drug candidate, is a small molecule,
administered orally, currently in clinical Phase 2b in sarcopenia (SARA-INT) in
the United States and Europe. A pediatric formulation of BIO101 is being
developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company
plans to start the clinical development in H2 2020.
Sarconeos (BIO101) will also be developed as a treatment for Covid-19
(Coronavirus) for which the company has filed a clinical trial application with
the French Regulatory Authority (ANSM).
The company is based in Paris, France, and Cambridge, Massachusetts. The
company's common shares are listed on the Euronext Growth Paris market (Ticker:
ALBPS -ISIN: FR0012816825). For more information www.biophytis.com.
Biophytis Contact for Investor Relations
Evelyne Nguyen, CFO e